Recombinant Human Endostatin Combined With Np Chemotherapy In Treatment Of Human Breast Cancer Xenograft In Nude Mice

Objective:This study was to investigate the anti-angiogenesis and tumor inhibitory effects of recombinant human endostatin (rhES) combined with vinorelbine-cisplatin chemotherapy (NP regimen) on xenograft tumors in nude mice of human breast carcinoma cell MDA-MB-435S.Method:Forty xenograft nude mice were randomized into 4 groups, that is NP group (vinorelbine 1mg/kg at days 1 and 8, and cisplatin lmg/kg at days 1 and 8, i. p.), rhES group (rhES 1.5mg/kg for 14 day, i. p.), rhES+NP group (combined treatment as above-mentioned), and control group (normal saline, i. p.). Inhibitory rate of xenograft and tumor growth curve was calculated and plotted. MVD, VEGF, HIF-la and P53 were measured by immunohistochemistry. Results:Tumor inhibition rate of combination group is 64.63%,but that of NP group is 35.47 %.Combination group compared with the other 3 groups, MVD and VEGF significantly reduced, the difference was statistically significant (p<0.05). HIF-1αin combination group was significantly lower than the control group, the difference was statistically significant (p<0.05). P53 expression in each group decreased compared with the control group, the difference was statistically significant (p<0.05). P53 combination group compared with the chemotherapy, the difference was statistically significant (p <0.05).Conclusion:Experiments showed that rhES combined with NP regimen can effectively control the tumor growth and decreases tumor MVD in nude mice, which may be down-regulate the expression of VEGF and HIF-la. The mechanism of endostatin on P53 needs our study.